RxDoctor Payments Data

Christina Council, MD

Family Medicine · North Bethesda, MDNPI 1831539451

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,795 of the $12,058 with a category attached, or 72.9%. Gilead accounts for 89.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $6,597 and has fallen 99.1% since, to $57 in 2025. Among family medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,058in general payments, 2019–2025

Across 51 payments — averaging $236.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$11K
  • AstraZeneca$268
  • Novo Nordisk$268
  • AbbVie$195
  • Medtronic$114
  • Boston Scientific$93
  • plus $299 from 9 others

What the payments were for

  • Speaking & faculty fees$8,79573%
  • Travel & lodging$1,42612%
  • Food & beverage$1,83615%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,058 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$59,965
Medicare patients
228
Services billed
1,048

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium167$2,000
Levothyroxine Sodium92$1,269
Metoprolol Succinate44$1,174
Losartan Potassium81$1,161
Amlodipine Besylate135$1,065
Rosuvastatin Calcium68$1,065
Azelastine Hcl29$1,017
SynthroidLevothyroxine Sodium14$989
Bupropion XlBupropion Hcl14$989
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid13$729
Fluticasone Propionate29$721
Esomeprazole Magnesium13$616
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide42$600
Trazodone Hcl33$560
Lisinopril59$557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$195$98914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in North Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →